Figure 6.
Dinaciclib inhibits RALB-TBK1 signaling and induces apoptosis in primary patient-derived AML cells. (Top) Relative mean fluorescence intensity (MFI) of phosphorylated TBK1 (pTBK1) and (bottom) percentage of cells with cleaved caspase-3 (cCASP3+) in individual AML patient samples (AML, n=5) or mononuclear cells from healthy granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood donors (MPBs, n=3) after 24 h treatment with dinaciclib measured by flow cytometry.